Purpose:

To evaluate the efficacy and safety of sustained release bimatoprost implant in a multi-center private practice setting in a variety of glaucoma patients

Methods:

Retrospective review of patients underwent implantation of a sustained release bimatoprost (Durysta) implant. Data was collected at the 1 day, 1 week, 1 month, 3 months, 6 months and beyond. Endpoints examined include the IOP lowering through Week 12 and the percentage of patients achieving ≥20%, ≥25%, ≥30%, ≥35%, and ≥40% IOP lowering. Number of topical medications at each visit was also recorded and analyzed. Data will be stratified based on severity of glaucoma, starting IOP, crystalline lens status, and if previous glaucoma surgery had been performed.

Results:

73 eyes from 44 patients were reviewed. Pre op IOP was 22.62 mm Hg and pre op glaucoma medications were 1.96. At 2 weeks post implant IOP was 20.54 and number of glaucoma medications were 1.71. At 6 weeks post implant IOP was 19.87 and number of glaucoma medications were 1.43. At 12 weeks post implant IOP was 19.73 and number of glaucoma medications were 1.52. At 15 weeks post implant IOP was 19.90 and number of glaucoma medications were 1.15. 10 patients went on to further intervention during the study period. Of the 10 patients, 8 of them had a corneal hysteresis that was less than 9.0 at the time of the injection, and 1 of them did not have corneal hysteresis recorded prior to injection.

Conclusions:

Treatment with sustained release bimatoprost implant resulted in lower topical glaucoma medication use while maintaining IOP in a diverse patient population. Certain subsets of patients, including those with higher corneal hysteresis, may have a more favorable outcome